Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …

Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

The cancer treatment landscape has changed dramatically since the turn of the century,
resulting in substantial improvements in outcomes for patients. This Review summarizes …

Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated
compared with those of healthy controls, but the sources of this extra cfDNA have never …

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …

Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade
lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform …

Early diagnosis has been proved to improve survival rate of lung cancer patients. The
availability of blood-based screening could increase early lung cancer patient uptake. Our …

Cancer is a term that denotes a group of diseases caused by the abnormal growth of cells
that can spread in different parts of the body. According to the World Health Organization …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …